1. An engineered multidomain bactericidal peptide as a model for targeted antibiotics against specific bacteria.
- Author
-
He Wang, Xiao-Fong Lu, Stephen R., Jie Zhang, Sheng-Fu Li, Stephen R., Gang Cheng, Li Yang, Jun-Yong Zuo, Stephen R., Yu-Qi Zhou, Stephen R., Hai-Yun Wang, Stephen R., Xin Cheng, Su-Hua Zhang, Stephen R., Zheng-Rong Ou, Stephen R., Zi-Cheng Zhong, Stephen R., Jing-Qiu Cheng, Stephen R., You-Ping Li, Stephen R., Lin Wan, Stephen R., Xiao-Qing Qiu, Stephen R., and Wu, George Y.
- Subjects
STAPHYLOCOCCAL diseases ,PHEROMONES ,METHICILLIN resistance ,STAPHYLOCOCCUS aureus ,STREPTOCOCCUS pneumoniae ,LABORATORY rats ,PEPTIDES ,THERAPEUTICS - Abstract
We constructed a peptide consisting of a staphylococcal AgrD1 pheromone fused to the channel-forming domain of colicin Ia and named it pheromonicin. This fusion peptide had bactericidal effects against methicillin-sensitive and methicillin-resistant Staphylococcus aureus (MSSA and MRSA, respectively), but not against Staphylococcus epidermidis or Streptococcus pneumoniae. Growth rates, vital staining and colony forming unit (CFU) counts showed that pheromonicin did not merely suppress growth but killed S. aureus cells. The specificity of pheromonicin was shown by the absence of bactericidal effects against an accessory gene regulator (agr) locus knockout of S. aureus, and a dose-dependent inhibition of the bactericidal effects of pheromonicin by competition with corresponding free AgrD pheromone. In vivo, all pheromonicin-treated mice survived administration of MRSA that was lethal to controls. No toxicity was detectable in human liver or renal cells in culture, or in livers, kidneys or spleens of pheromonicin-treated mice. The results suggest that these types of chimeric peptides may be of value as antibiotics against specific bacterial infections. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF